ADCT logo

ADCT
Adc Therapeutics SA

1,249
Mkt Cap
$487.14M
Volume
1.84M
52W High
$4.98
52W Low
$1.23
PE Ratio
-3.06
ADCT Fundamentals
Price
$3.68
Prev Close
$3.83
Open
$3.58
50D MA
$4.03
Beta
1.56
Avg. Volume
933,511.33
EPS (Annual)
-$1.12
P/B
-2.49
Rev/Employee
$421,538.86
$626.76
Loading...
Loading...

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available
Poll

Earnings Recap

• Reported GAAP EPS of -$0.21 up 41.67% YoY • Reported revenue of $20.85M down -9.47% YoY • ADC Therapeutics expects LOTIS-5 Phase 3 topline data in Q2 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end, and maintains an expected cash runway at least into 2028.

Bullish

ADC Therapeutics achieved increased net product revenues and reduced R&D expense, alongside anticipated Q2 2026 topline data for the pivotal ZYNLONTA LOTIS-5 Phase 3 trial.

Bearish

ADC Therapeutics experienced a decline in total net revenue to $20.85M, faced increased cost of product sales, and saw cash and cash equivalents decrease to $231M due to operations.

Latest ADCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.